Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

More evidence links heartburn drugs to serious kidney problems

People taking common heartburn medications known as proton pump inhibitors (PPIs) are at increased risk of new and severe kidney disease, according to a U.S. study. Among hundreds of thousands of patients in Department of Veterans Affairs (VA) databases, new users of PPIs without kidney disease were 30 percent more likely to develop chronic kidney […]

Read More »

U.S. agencies issues rules to protect workers from Zika

U.S. health and safety officials issued new guidelines on Friday to help protect workers from exposure to Zika, a mosquito-borne and sexually-transmitted virus that causes the birth defect microcephaly and other neurological disorders.   The new rules, issued by the Centers for Disease Control and Prevention and the Occupational Safety and Health Administration, urge employers […]

Read More »

FDA proposes ban on certain electrical stimulation devices

The U.S. Food and Drug Administration on Friday proposed a ban on electrical stimulation devices (ESDs) that are used to curb individuals from engaging in self-injurious or aggressive behavior, saying they pose an “unreasonable and substantial” risk to public health. ESDs administer electrical shocks through electrodes attached to the skin to attempt to condition to […]

Read More »

Healthcare Agencies Celebrated at Med Ad News’ 2016 Manny Awards

Med Ad News announces the winners for the 2016 Manny Awards, celebrating the best in healthcare advertising.

Read More »

Eisai Company Beefs Up Neurology Team with Ex-Pfizer, Sanofi Execs

Eisai has bolstered its U.S. neurology leadership team by snagging executives from Sanofi and Pfizer to create and drive commercial strategies for the company.

Read More »

Deal Spree for AbbVie Continues with $500 Million Cancer Tie-Up with CytomX

AbbVie entered into a collaborative drug development agreement with CytomX Therapeutics to co-develop Probody Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1).

Read More »

AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep

AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm on the potential of genetic variations to unlock routes to new medicines.   The initiative, announced on Friday, involves sequencing up to 2 million human genomes – the complete set of genetic […]

Read More »

UK agency backs cancer drug after Sanofi cuts price

Britain’s healthcare cost watchdog NICE said on Friday it had changed its mind and decided to recommend Sanofi’s prostate cancer drug Jevtana after the French company agreed to a further discount.   The National Institute for Health and Care Excellence (NICE) said the improved discount was “an excellent example of how pharma companies can work […]

Read More »

Allergan Makes Another Deal, Bags Boston’s Topokine for $85 Million+

April 22, 2016By Mark Terry, BioSpace.com Breaking News Staff   It’s a toss-up on whether Dublin-based Allergan (AGN) is better known for Botox or for the failed Pfizer (PFE) merger, but today’s move suggests that Allergan knows. The company announced today it had acquired Boston-based Topokine Therapeutics. Along with the company comes XAF5, a first-in-class […]

Read More »

Senators close to proposal on Zika funds: Republican committee chairman

A bipartisan group of senators will soon offer a proposal for more funding to fight a Zika outbreak spreading rapidly through the Americas, Senate Appropriations Committee Chairman Thad Cochran said on Thursday.   Democrats and Obama administration officials have urged the Republican-controlled Congress to grant nearly $1.9 billion in emergency funds to combat Zika, a […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom